|
ZBTB9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.87909998672353E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.65739996463799E-09 |
| Normal-vs-Stage2 |
9.90130000000367E-05 |
| Normal-vs-Stage3 |
4.8134052299531E-11 |
| Normal-vs-Stage4 |
1.51589962804621E-10 |
| Stage1-vs-Stage2 |
1.573580E-01 |
| Stage1-vs-Stage3 |
2.426000E-01 |
| Stage1-vs-Stage4 |
3.468500E-02 |
| Stage2-vs-Stage3 |
4.700000E-02 |
| Stage2-vs-Stage4 |
6.384400E-03 |
| Stage3-vs-Stage4 |
2.812600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.19539994464435E-09 |
| Normal-vs-AfricanAmerican |
1.52914999999032E-05 |
| Normal-vs-Asian |
8.46720000000634E-05 |
| Caucasian-vs-AfricanAmerican |
5.211800E-01 |
| Caucasian-vs-Asian |
6.543800E-02 |
| AfricanAmerican-vs-Asian |
7.096300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.34329999848626E-10 |
| Normal-vs-Female |
2.423899969628E-09 |
| Male-vs-Female |
8.515200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.68120003976691E-09 |
| Normal-vs-Age(41-60Yrs) |
4.70179450928754E-11 |
| Normal-vs-Age(61-80Yrs) |
3.71609965021946E-10 |
| Normal-vs-Age(81-100Yrs) |
2.357700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.912400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.623800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.208600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.182000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.621200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.247000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.878700E-03 |
| Classical-VS-Follicular |
3.815900E-03 |
| Classical-VS-Other |
4.227400E-01 |
| Classical-VS-Normal |
1.30420000021836E-07 |
| Tall-VS-Follicular |
7.219200E-01 |
| Tall-VS-Other |
9.528800E-01 |
| Tall-VS-Normal |
9.39490041318436E-10 |
| Follicular-VS-Other |
8.178000E-01 |
| Follicular-VS-Normal |
3.30130367487413E-11 |
| Other-VS-Normal |
3.456000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.13910017371677E-10 |
| Normal-vs-N1 |
9.41691169487058E-12 |
| N0-vs-N1 |
3.024300E-03 |
|
|
